Form 4: Avanos Medical SVP, Operations, Sigfrido Delgado, Reports Acquisition and Disposal of Shares

Sigfrido Delgado, SVP of Operations at Avanos Medical, reports acquiring shares through restricted stock units and disposing of shares, along with acquiring employee stock options.

Summary

• On March 7, 2025, Sigfrido Delgado, SVP of Operations at Avanos Medical, reported transactions involving Avanos Medical common stock and derivative securities.
• Delgado acquired 10,213 shares of common stock through time-based restricted share units (TRSUs) at $0.
• These TRSUs will vest in three equal installments on March 7, 2026, March 7, 2027, and March 7, 2028.
• Delgado also disposed of 27,819 shares of common stock.
• Additionally, Delgado acquired 21,914 employee stock options with an exercise price of $15.24, exercisable starting March 7, 2025, and expiring on March 7, 2035.
• These options will vest 30% on March 7, 2026, 30% on March 7, 2027, and 40% on March 7, 2028.
• Following these transactions, Delgado directly owns 21,914 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The filing reflects routine transactions related to executive compensation. The acquisition of shares and options is mildly positive, while the disposal of shares is mildly negative, resulting in a balanced outlook.

Positives

• The acquisition of restricted stock units and employee stock options suggests a long-term commitment to the company by the SVP of Operations.

Negatives

• The disposal of 27,819 shares could be interpreted negatively, although the reason for disposal is not specified.

Risks

• The vesting of the restricted stock units and stock options is contingent upon continued employment and other factors, which could be affected by unforeseen circumstances.

Future Outlook

The vesting schedule of the restricted stock units and stock options indicates a multi-year incentive plan for the reporting person.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.

Comparison to Industry Standards

• Stock option and restricted stock unit grants are common compensation practices among publicly traded companies to align management's interests with those of shareholders.
• Vesting schedules of three years are typical for such grants, aligning with industry norms for long-term incentive plans.
• Comparing the size of the grant to similar roles at peer companies like Medtronic or Boston Scientific would provide further context on the competitiveness of Avanos Medical's compensation packages.

Stakeholder Impact

• The transactions may have a minor impact on shareholders by signaling management's confidence (or lack thereof) in the company's future performance.
• Employees may be affected by the vesting of stock options and restricted stock units, which can impact morale and retention.

Key Dates